Effect of US Contrast Agents on Spectral Velocities: In Vitro Evaluation1
Michelle L. Melany, MD,
Edward G. Grant, MD,
Shella Farooki, MD,
David McElroy, BS and
Carolyn Kimme-Smith, PhD
1 From the Department of Radiological Sciences, University of California, Los Angeles, Medical Center, 10833 Le Conte Ave, M/C 172115, Los Angeles, CA 90095-1721 (M.L.M., S.F., D.M., C.K.S.), and the Department of Radiology, West Los Angeles Veterans Affairs Medical Center, Los Angeles, Calif (E.G.G.). Received June 10, 1998; revision requested July 27; revision received August 17; accepted October 14. Address reprint requests to M.L.M.

View larger version (130K):
[in a new window]
|
Figure 1. Photograph shows the flow pump and flowmeter (left side of image) connected with plastic tubing to the flow phantom (right side of image), which has a scanning well and four channels.
|
|

View larger version (112K):
[in a new window]
|
Figure 2a. Spectral Doppler images show the peak systolic velocity (PSV) and end-diastolic velocity (EDV) measured proximal to the stenosis in the 75% stenosis vessel model. (a) Before contrast agent administration, the peak velocity is 39.9 cm/sec. (b) After contrast agent administration, the peak velocity is 35.9 cm/sec. The gray-scale image shows enhancement in the phantom.
|
|

View larger version (112K):
[in a new window]
|
Figure 2b. Spectral Doppler images show the peak systolic velocity (PSV) and end-diastolic velocity (EDV) measured proximal to the stenosis in the 75% stenosis vessel model. (a) Before contrast agent administration, the peak velocity is 39.9 cm/sec. (b) After contrast agent administration, the peak velocity is 35.9 cm/sec. The gray-scale image shows enhancement in the phantom.
|
|
Copyright © 1999 by the Radiological Society of North America.